Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283871 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1RAB9AKMT2ANR4A2 | |
| SCHEMBL8219820 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2MAOBAOC3MEN1RAB9A | |
| SCHEMBL9219214 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1KMT2ACYP3A4HIF1A | |
| SCHEMBL628857 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MAOBAOC3MEN1RAB9A | |
| SCHEMBL733369 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MAOBAOC3MEN1RAB9A | |
| SCHEMBL6153892 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MAOBAOC3MEN1RAB9A | |
| Hydrochloric Acid SCHEMBL4640626 | 0.81 | SMN1; SMN2 (0.96) | SMN1; SMN2MEN1RAB9AKMT2ANR4A2 | |
| SCHEMBL12622683 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MAOBAOC3MEN1RAB9A | |
| Ammonia Solution, Strong SCHEMBL28429402 | 0.81 | SMN1; SMN2 (0.96) | SMN1; SMN2MEN1RAB9AKMT2ANR4A2 | |
| SCHEMBL11220885 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2MAOBAOC3LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998000434-A1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 1998-01-08 | — | — | WO | claimed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-1998000434-A1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 1998-01-08 | — | — | WO | disclosed |
| US-5294530-A | amine developers emulsion layer containing a yellow or cyan coupler and a phenolic derivative | FUJI PHOTO FILM CO., LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5104782-A | Silver halide color photographic material containing a pyrazoloazole based coupler and having excellent color reproduction characteristics and which provides images having excellent light fastness | FUJI PHOTO FILM CO., LTD. (JP) | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | SMN1; SMN2 2211/4885MAOB 3660/4885AOC3 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.